Felbamate Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Epilepsy

Adjunctive therapy: 1200 mg/day in 3-4 divided doses. The daily dose can be increased in 1200 mg increments each week as tolerated to response. Maximum daily dose: 3600 mg.

Monotherapy: 1200 mg/day in 3-4 divided doses. Increase the daily dose in 600 mg increments every two weeks as tolerated to response.

Conversion to monotherapy: 1200 mg/day in 3-4 divided doses. Starting at week 2 the daily dose can be increased in 1200 mg increments weekly. Maximum daily dose: 3600 mg. The dose of concomitant anticonvulsants should be decreased by 1/3 of the original dose at the start of felbamate therapy, when felbamate is increased at week 2, and as clinically necessary.

Usual Pediatric Dose for Lennox-Gastaut Syndrome

>2 years to 14 years with Lennox-Gastaut Syndrome:

Adjunctive therapy: 15 mg/kg/day in 3-4 divided doses. Initial therapy should include reducing the dose of concomitant anticonvulsants by 20%. Increase the dosage of felbamate by 15 mg/kg/day in weekly intervals as tolerated to desired clinical response. Maximum daily dosage: 45 mg/kg/day. Further dosage reductions of concomitant anticonvulsants may be necessary to reduce side effects due to drug interactions.

Liver Dose Adjustments

Felbamate taken by itself or with other prescription and/or nonprescription drugs, can result in a severe, potentially fatal blood abnormality ("aplastic anemia") and/or severe, potentially fatal liver damage.

Precautions

Felbamate taken by itself or with other prescription and/or nonprescription drugs, can result in a severe, potentially fatal blood abnormality ("aplastic anemia") and/or severe, potentially fatal liver damage.

Felbamate should not be used by patients until there has been a complete discussion of the risks and the patient,parent, or guardian has provided written informed consent.
A patient information/consent form is included with the product package insert. The form can also be obtained by contacting the local Wallace representative or calling 609-655-6147.

Other Comments

Felbamate taken by itself or with other prescription and/or nonprescription drugs, can result in a severe, potentially fatal blood abnormality ("aplastic anemia") and/or severe, potentially fatal liver damage.

Felbamate should not be used by patients until there has been a complete discussion of the risks and the patient,parent, or guardian has provided written informed consent.

Hide
(web1)